References
- Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
- Rimsza LM, Roberts RA, Miller TP, et al Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103: 4251–4258.
- Rimsza LM, Leblanc ML, Unger JM, et al Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425–3433.
- Roberts RA, Wright G, Rosenwald AR, et al Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006;108:311–318.
- Steimle V, Otten LA, Zufferey M, et al Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993;75:135–146.
- Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006;27:405–412.
- Cycon KA, Rimsza LM, Murphy SP. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol 2009;37:184–194.
- Muhlethaler-Mottet A, Otten LA, Steimle V, et al Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997;16:2851–2860.
- Rimsza LM, Roberts RA, Campo E, et al Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006;107: 1101–1107.
- Rimsza LM, Chan WC, Gascoyne RD, et al CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009;94:596–598.
- Morris AC, Spangler WE, Boss JM. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J Immunol 2000;164:4143–4149.
- Morimoto Y, Toyota M, Satoh A, et al Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 2004;90:844–852.
- Frommer M, McDonald LE, Millar DS, et al A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827–1831.
- Accolla RS. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets. J Exp Med 1983;157:1053–1058.
- Morris AC, Beresford GW, Mooney MR, et al Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 2002;22:4781–4791.